biostudies-literatureWu DChinese Academy of Medical Sciences Innovation Fund for Medical SciencesPhysician Growth Plan for Digestive Tract Cancers and Precancers7050https://www.ebi.ac.uk/biostudies/studies/S-EPMC9739995biostudies-literatureUnknown11(23)Background: Quadruple therapy with polaprezinc provided an alternative to Helicobacter pylori eradication; however, the effect on gut microbiota remains uncertain. This study aims to identify whether polaprezinc-containing quadruple therapy causes adverse microbiota effects among asymptomatic adults, compared with bismuth therapy. Methods: This was a randomized control trial. One hundred asymptomatic H. pylori-infected adults were randomly (1:1) assigned to two treatment groups (polaprezinc-containing therapy, PQT; or bismuth-containing therapy, BQT). Fecal samples were collected from subjects before and 4−8 weeks after therapy. Samples were sequenced for the V4 regions of the 16S rRNA gene. Results: The relative abundance of the three dominant bacterial phyla (Bacteroidota, Firmicutes, anJournal of clinical medicineThe Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial.PMC97399952016-I2M-3-001GTCZ-2020-SC-51-0010Xie WLi JQin JJiang HWu DSun ZZhao YLi XLiu YLi TChen WWu WTan QChen TfalseThe Effect of Quadruple Therapy with Polaprezinc or Bismuth on Gut Microbiota after <i>Helicobacter pylori</i> Eradication: A Randomized Controlled Trial.Background: Quadruple therapy with polaprezinc provided an alternative to Helicobacter pylori eradication; however, the effect on gut microbiota remains uncertain. This study aims to identify whether polaprezinc-containing quadruple therapy causes adverse microbiota effects among asymptomatic adults, compared with bismuth therapy. Methods: This was a randomized control trial. One hundred asymptomatic H. pylori-infected adults were randomly (1:1) assigned to two treatment groups (polaprezinc-containing therapy, PQT; or bismuth-containing therapy, BQT). Fecal samples were collected from subjects before and 4−8 weeks after therapy. Samples were sequenced for the V4 regions of the 16S rRNA gene. Results: The relative abundance of the three dominant bacterial phyla (Bacteroidota, Firmicutes, an2022-01-01T00:00:00Z2022 Nov2026-06-20T03:22:56.638Z2025-04-20T03:35:19.991ZS-EPMC97399953649862410.3390/jcm11237050